Corporate News

Concepta pre-launch myLotus in the UK

28 March 2018

Concepta plc (AIM: CPT) the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it showcased its myLotus products at the Manchester Fertility Show on 24 and 25 March 2018.

Concepta announced the forthcoming launch of its myLotus products in the UK at the event which was attended by 53 specialised fertility exhibitors and approximately 1,200 people with fertility issues. The Company is currently in the final stages of the CE-marking process for myLotus and the product is expected to be available in the UK in H2 2018, once the final audit by the British Standards Institution

("BSI") is complete. 

The myLotus website is now live and the Company's pre-launch digital marketing strategy has commenced. The consumer twitter page for myLotus is now active at

Erik Henau, CEO of Concepta commented: "The event was a great success and consumer feedback has been excellent, with many women and fertility support groups registering to be kept updated on the launch date of myLotus products in the UK.

"Having launched our myLotus website, our focus is now on driving marketing and raising further awareness of Concepta and myLotus products in our home market, in anticipation of its launch in the latter half of the year."



The Company

Erik Henau


Tel: +44 (0) 1234 866601


SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550


NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400


Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254


Notes to Editors

Concepta Plc

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and human chorionic gonadotropin (hCG) hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future. 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated

 target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.


About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.